16.12.2021 SHOP APOTHEKE EUROPE N.V.  NL0012044747

DGAP-News: SHOP APOTHEKE EUROPE Launches its Own Marketplace.


 

DGAP-News: SHOP APOTHEKE EUROPE N.V. / Key word(s): Strategic Company Decision/Market launch
SHOP APOTHEKE EUROPE Launches its Own Marketplace.

16.12.2021 / 07:00
The issuer is solely responsible for the content of this announcement.


SHOP APOTHEKE EUROPE Launches its Own Marketplace.

Sevenum, the Netherlands, 16 December 2021. SHOP APOTHEKE EUROPE launched its marketplace in Germany this week - another milestone for one of Europe's leading e-pharmacies.

SHOP APOTHEKE EUROPE recognises the potential of the marketplace model to meet and exceed consumer demands and to pursue the company's development from an online retailer into Europe's leading customer-centric e-pharmacy platform.

Patrick Schneider, Executive Director, Marketplace & Same-day Service: says: "The new marketplace, which has been integrated into our existing SHOP APOTHEKE platform, has numerous benefits for both our customers and our external partners. Thanks to the new marketplace, we can offer our customers a much wider range of products for their health. Our selected partners benefit from our vast customer base with high customer loyalty as well as from our easy-to-use technology platform."

The SHOP APOTHEKE marketplace starts with 20,000 additional new products, carefully curated from over 30 partner sellers. The number of new products will grow to over 50,000 in the near future. In addition, it is already planned for next year to roll out the marketplace offer to other countries where SHOP APOTHEKE EUROPE has a market-leading position as well as to significantly increase the number of products and partners in all countries. The remarkably larger product selection generally leads to a wider reach and scalability of the SHOP APOTHEKE platform. Furthermore, customers can also collect RedPoints from the SHOP APOTHEKE benefits programme on marketplace products.

Stefan Feltens, CEO of SHOP APOTHEKE EUROPE, comments: "All third-party suppliers for our new marketplace are carefully vetted before being selected to join. The scalable platform technology will allow us to further increase our product offering and the number of partners. Besides that we are able to add new categories in a controlled way, so that we can maintain the quality of products and service we are used to providing to our customers."

For more information on the SHOP APOTHEKE marketplace, please visit:

https://www.shop-apotheke.com/lp/marktplatz/
 

About SHOP APOTHEKE EUROPE.

SHOP APOTHEKE EUROPE is one of Europe's leading and fastest-growing online pharmacies, currently operating in Germany, Austria, France, Belgium, Italy, the Netherlands and Switzerland.

Headquartered in the Dutch logistics hub of Sevenum near Venlo with locations in Cologne, Berlin, Munich, Tongeren, Warsaw, Milan, Lille and Eindhoven, SHOP APOTHEKE EUROPE offers its customers a broad range of more than 100,000 original products at attractive prices: OTC, beauty and personal care products as well as prescription drugs, supplemented by high quality natural food and health products, low carb products and sports nutrition. Currently, 7.3 million active customers trust SHOP APOTHEKE EUROPE.

Since safe and reliable pharmaceutical advice are top priorities at SHOP APOTHEKE EUROPE, the e-pharmacy provides comprehensive pharmaceutical consulting services.

In preparation for the introduction of electronic prescriptions in Germany, the company will further improve the customer experience with a focus on disease-specific digital medication management services following the acquisition of SMARTPATIENT in January 2021. This is a key part of SHOP APOTHEKE EUROPE's strategy to transform itself from a pure online retailer into a truly customer-centric e-pharmacy platform.

SHOP APOTHEKE EUROPE N.V. has been listed on the regulated market of the Frankfurt Stock Exchange (Prime Standard) since 2016 and is part of the SDAX stock index.

PRESS CONTACTS.

Trade and popular media:
Sven Schirmer
Tel: +49 221 99 53 44 31
Email: [email protected]

Financial media:
Bettina Fries
Tel: +49 211 75 80 779
Email: [email protected]

Investor relations:
Carmen Herkenrath
Tel.: +31 77 850 6109
Email: [email protected]

Thomas Schnorrenberg
Mobile: +49 151 465 31317
Email: [email protected]



16.12.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: SHOP APOTHEKE EUROPE N.V.
Dirk Hartogweg 14
5928 LV Venlo
Netherlands
Phone: 0800 - 200 800 300
Fax: 0800 - 90 70 90 20
E-mail: [email protected]
Internet: www.shop-apotheke-europe.com
ISIN: NL0012044747, DE000A19Y072
WKN: A2AR94, A19Y07
Indices: SDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1258483

 
End of News DGAP News Service

1258483  16.12.2021 

fncls.ssp?fn=show_t_gif&application_id=1258483&application_name=news&site_id=boersengefluester_html


Die wichtigsten Finanzdaten auf einen Blick
  2017 2018 2019 2020 2021 2022 2023e
Umsatzerlöse1 283,99 539,71 701,01 968,06 1.060,32 1.204,35 1.798,76
EBITDA1,2 -12,14 -15,56 -18,58 15,20 -38,73 -29,66 39,99
EBITDA-Marge3 -4,27 -2,88 -2,65 1,57 -3,65 -2,46
EBIT1,4 -19,20 -28,73 -33,45 -0,87 -65,70 -69,17 -17,30
EBIT-Marge5 -6,76 -5,32 -4,77 -0,09 -6,20 -5,74 -0,96
Jahresüberschuss1 -21,36 -33,61 -36,27 -16,77 -74,19 -77,65 -11,61
Netto-Marge6 -7,52 -6,23 -5,17 -1,73 -7,00 -6,45 -0,65
Cashflow1,7 -23,24 -23,54 -30,37 17,80 11,64 -29,11 61,46
Ergebnis je Aktie8 -2,25 -2,79 -2,78 -1,17 -4,15 -4,32 -0,73
Dividende8 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2023 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: Mazars

INVESTOR-INFORMATIONEN
©boersengefluester.de
Redcare Pharmacy
WKN Kurs in € Einschätzung Börsenwert in Mio. €
A2AR94 132,200 Halten 2.689,28
KGV 2025e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
73,44 0,00 0,00 -63,31
KBV KCV KUV EV/EBITDA
5,15 43,76 1,50 71,35
Dividende '22 in € Dividende '23e in € Div.-Rendite '23e
in %
Hauptversammlung
0,00 0,00 0,00 17.04.2024
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
25.04.2024 30.07.2024 05.11.2024 05.03.2024
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
-4,88% 8,49% 0,92% 49,11%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu SHOP APOTHEKE EUROPE N.V.  ISIN: NL0012044747 können Sie bei EQS abrufen


E-Commerce , A2AR94 , RDC , XETR:RDC